Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis

Although the COVID-19 vaccines are currently recommended for people with myasthenia gravis (MG), there is no data regarding the safety of the vaccines in this population. In order to investigate the real-life safety data of the BNT162b2 COVID-19 vaccine in people with MG, an anonymous survey was dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Lotan, Itay, Hellmann, Mark A., Friedman, Yitzhak, Stiebel-Kalish, Hadas, Steiner, Israel, Wilf-Yarkoni, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817458/
https://www.ncbi.nlm.nih.gov/pubmed/35227552
http://dx.doi.org/10.1016/j.nmd.2022.01.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817458/
https://www.ncbi.nlm.nih.gov/pubmed/35227552
http://dx.doi.org/10.1016/j.nmd.2022.01.013

Ejemplares similares